GE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Pioneer System, nuclear magnetic resonance imaging system.
Publicado el 16 de febrero de 2022 · Inicio del retiro: 23 de diciembre de 2021
Resumen
FDA registra el retiro Z-0592-2022 de dispositivos médicos de Clase II, publicado el 16 de febrero de 2022 e iniciado el 23 de diciembre de 2021. Empresa responsable: GE Healthcare, LLC; Estado: En curso; Cantidad reportada: 17,228 devices total in this field correction; Lote: All systems. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
The magnetic resonance systems could potentially have a cryogen ventilation system that does not meet the venting requirements.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- GE Healthcare, LLC
- Distribuidor
- Distribution was nationwide, including Puerto Rico and the Virgin Islands. There was also government and military distribution. Foreign distribution was made to Albania, Algeria, Argentina, Armenia, Australia, Austria, Azerbaidjan, Bahrain, Bangladesh, Belarus, Belgium, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Bulgaria, Cambodia, Canada, Chile, China, Colombia, Republic of Congo, Croatia, Cyprus, Czech Republic, Denmark, Djibouti, Dominican Republic, Ecuador, Egypt, Equatorial Guinea, Estonia, Ethiopia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Honduras, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Korea, Kuwait, Kyrhyzstan, Latvia, Lebanon, Libyan Arabic Jamahiriya, Lithuania, Luxembourg, Macedonia, Madagascar, Malaysia, Mali, Malta, Mauritania, Mexico, Republic of Moldova, Morocco, Mozambique, Myanmar, Nepal, Netherlands, New Zealand, Nicaragua, Nigeria, Nordic-HQ, Norway, Oman, Pakistan, State of Palestine, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sudan, Swaziland, Sweden, Switzerland, Syria, Taiwan, Tanzania, Thailand, Trinidad and Tobago, Tunisia, Turkey, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Uzbekistan, Venezuela, Vietnam, Zambia, and Zimbabwe.
- Lote
- All systems.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDACentricity PACS Software Version 7.0 SP0.0.4.73 de agosto de 2022
- FDASIGNA Premier magnetic resonance scanner, model 5748519.27 de julio de 2022
- FDAGE Centricity Universal Viewer Zero Footprint. To view, communicate, process, and display Medical images and13 de julio de 2022
- FDABack up batteries in Avance CS2 and Avance CS2 Pro anesthesia devices manufactured on or after April 1, 20196 de julio de 2022
- FDAGE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Architect system, nuclear16 de febrero de 2022
- FDAGE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Voyager and SIGNA Voyager Premier16 de febrero de 2022
Preguntas sobre este retiro
¿GE Healthcare MR superconducting magnets, a component of GE Healthcare SIGNA Pioneer System, nuclear magnetic resonance imaging system. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0592-2022 el 16 de febrero de 2022. Peligro reportado: The magnetic resonance systems could potentially have a cryogen ventilation system that does not meet the venting requirements.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter